Nexus Pharmaceuticals to open Wisconsin facility
LINCOLNSHIRE -- Nexus Pharmaceuticals Inc. said it has received approval from the village of Pleasant Prairie, Wisconsin, to occupy its new pharmaceutical manufacturing facility.
Nexus, which develops and manufactures specialty and generic injectables drugs, first announced its plans in 2019 to build Project Tomorrow, a state-of-the-art sterile injectable manufacturing facility. The plant will support the production of injectable drugs in various therapeutic areas such as anesthesiology, oncology, cardiology, and neurology.
Project Tomorrow, in which Nexus plans to invest $250 million, is projected to be completed in three phases within the next ten years. Phase one, which began in August 2019, includes a three-story manufacturing facility with an advanced isolator filling system.
Nexus and the village of Pleasant Prairie partnered with Integrated Project Services and Turner Construction on the design and construction of the 84,000-square-foot structure. Nexus is planning the development of phases two and three, which will include cytotoxic and highly potent manufacturing suites, increased warehousing and expanded secondary packaging.
"This is a critical milestone and brings us one step closer to manufacturing critical and essential medications in the United States," said Mariam S. Darsot, Nexus president and CEO.
Nexus anticipates completing phase one hiring and operations by this fall, which will create 77 new jobs in the fields of high-tech manufacturing and scientific research.